Ensayo clínico de fase II, de optimización de dosis, abierto, de Zalypsis (PM00104) en pacientes con mieloma múltiple recaído/refractario

Trial Profile

Ensayo clínico de fase II, de optimización de dosis, abierto, de Zalypsis (PM00104) en pacientes con mieloma múltiple recaído/refractario

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2011

At a glance

  • Drugs PM 00104 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 21 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top